Join our daily newsletter At The Bell to receive exclusive market insights
With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front of those trends is so important for any trader worth their salt.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
In this daily HotCopper Trends column, we break down the top three stocks talked about on any given trade day, and why they’ve drawn a daily focus.
This is a nice one because I’ve been on a little break, so we’re getting back into the swing of things with CY26’s Trends – and while it hasn’t been the busiest Monday we’ll see through the year, there’s still plenty on.
Metallium (ASX:MTM) claims our top spot in the first Trends column of the year after signing a deal with Glencore that will now see the latter give Metallium e-scrap feedstock for Metallium’s own e-waste recycling ventures.
Price-wise, it looks like shareholders weren’t overly happy; MTM has dumped as much as -7% through Monday’s trading day to just under $1/share.
Elsewhere, Island Pharmaceuticals (ASX:ILA) caught attention on news that they’ve secured an “ongoing arrangement” with the FDA, which will see the U.S. body review Island’s Galidesivir development sometime soon.
And finally, excitement has bubbled up around Fenix Resources (ASX:FEX) early in the first week of the CY26 trade after its December production update. In the report, Fenix confirmed it had shipped as much as 1.2M wet metric tonnes of iron ore and banked around $79 million through its efforts.
Price-wise, FEX were up +2.5%, at around 49cps.
And looking wider, the ASX 200 has been down around -0.08%.
That’s Monday’s HotCopper Market Trends, I’m Isaac McIntyre – see you for close.
Join the discussion. See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
